May 8, 2025 (press release) –
Schreiner MediPharm presents the Digital Display Label, a pioneering solution for digital marking of investigational drugs in clinical trials. This innovative technology has the potential to replace conventional labels by electronic ones with digital displays in the future. That makes it possible to eliminate the need for time-consuming manual relabeling, enables significant process optimization during clinical trials, and helps shorten time-to-market.
Clinical trials entail exacting requirements: Flexibility, speed, and precision are crucial, and conventional labels with static information soon reach their limits in that regard. Changes to protocol numbers, patient groups, or expiration dates as well as regulatory modifications require manual relabeling of the investigational drugs in many countries, which causes delays and costs.
Modular System for a Variety of Packaging Forms
The new Digital Display Label from Schreiner MediPharm remedies this situation: It is based on a modular, reusable plastic housing reliably protecting the sensitive display electronics. A carefully conceived adapter system ensures ease of application to a variety of packaging forms–be it flat blister wallets and kit boxes or round containers like plastic bottles and vials. For transparent containers, additional features such as light protection or blinding can be integrated.
Sustainability Due to Reusability
In terms of sustainability, the new approach by Schreiner MediPharm is a compelling solution as well: Both the housing and the adapter system are reusable, which conserves resources and avoids waste. The modular design enables integration into existing standard packaging without requiring modifications. At the same time, the system ensures a reliable connection between the Digital Display Label and the primary container or packaging.
In total, the Digital Display Label not only enhances efficiency in clinical trial logistics but also accelerates the entire trial process while offering research-based pharmaceutical companies significant savings potential and higher patient compliance–a crucial move toward modern, digital clinical trial procedures.
* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistribute or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.